Latest from Ashley Yeo
Insight into the knock-on effects on innovation adoption and procurement is keenly awaited by medtechs.
New funding mechanisms are required to give more momentum to prevention in the community and thereby relieve pressure on overburdened health care providers like the UK National Health Service. So says Simon Radford, a director at global thinktank the Milken Institute, which sees a solution in more funding for community-level prevention.
Germany’s Union parties may have little alternative than to bring the SPD into a new four-year coalition, says Clifford Chance partner and life sciences legal expert Gunnar Sachs. Health policy will likely see both textural and structural changes.
Most fees and fee uplifts proposed by the UK MHRA to begin in April 2025 will be implemented on schedule. A general 8.85% increase will be applied to all statutory fees, but the new medical devices registration fee is subject to ongoing review and/or alternative options.
Germany’s Union parties may have little alternative than to bring the SPD into a new four-year coalition, says Clifford Chance partner and life sciences legal expert Gunnar Sachs. Health policy will likely see both textural and structural changes.
Lawrence Tallon will succeed June Raine as MHRA chief executive on 1 April. UK medtechs will prioritize an early meeting with the man who since 2020 has served as deputy chief executive of Guy’s and St Thomas' NHS Trust.